Finance

Beta
Lists
NRX:CVE
Nurexone Biologic Inc
CA$0.57
0.00%
(0.00) 1D
Jun 29, 3:57:18 PM GMT-4  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for NRX...
Mkt. cap
52.47M
Avg. vol.
13.18K
Volume
0.00
52-wk high
CA$1.14
52-wk low
CA$0.51
EPS
-CA$0.11
Beta
0.15
Shares outstanding
92.05M
No. of employees
9
Mkt. cap
52.47M
Avg. vol.
13.18K
Volume
0.00
52-wk high
CA$1.14
52-wk low
CA$0.51
EPS
-CA$0.11
Beta
0.15
Shares outstanding
92.05M
No. of employees
9
News stories
From sources across the web
About Nurexone Biologic Inc
CEO-
Employees9
Founded2011
Headquarters-
SectorBiotechnology
Websitenurexone.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
697.00K
703.00K
619.00K
630.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.12M
763.00K
716.00K
1.13M
Operating expense
1.82M
1.47M
1.34M
1.76M
Total operating expenses
1.82M
1.47M
1.34M
1.76M
Operating income
-1.82M
-1.47M
-1.34M
-1.76M
Other non operating income
-
-20.00K
5.00K
-6.00K
EBT including unusual items
-1.85M
-1.46M
-1.40M
-1.77M
EBT excluding unusual items
-1.85M
-1.46M
-1.40M
-1.77M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-1.85M
-1.46M
-1.40M
-1.77M
Net profit margin
-
-
-
-
Earnings per share
-0.02
-0.02
-0.02
-0.02
Interest and investment income
9.00K
21.00K
27.00K
6.00K
Interest expense
-33.00K
-
-43.00K
-9.00K
Net interest expenses
-24.00K
21.00K
-16.00K
-3.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.78M
-1.42M
-1.31M
-1.70M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer